Evidence map›Paper›PMID 28385713›Full record

ArticleGenome research2017

Genome-wide TOP2A DNA cleavage is biased toward translocated and highly transcribed loci.

Xiang Yu, James W Davenport, Karen A Urtishak, Marie L Carillo, Sager J Gosai, Christos P Kolaris, Jo Ann W Byl, Eric F Rappaport, Neil Osheroff, Brian D Gregory and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Genome research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Recurrent mutations in topoisomerase IIα cause a previously undescribed mutator phenotype in human cancers.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Xiang YuBiology Department, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
James W DavenportDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA.
Karen A UrtishakDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA.
Marie L CarilloDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA.
Sager J GosaiBiology Department, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Christos P KolarisDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA.
Jo Ann W BylDepartment of Biochemistry, Vanderbilt University, Nashville, Tennessee 37232, USA.
Eric F RappaportNAPCore, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA.
Neil OsheroffDepartment of Biochemistry, Vanderbilt University, Nashville, Tennessee 37232, USA.
Brian D GregoryBiology Department, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Carolyn A FelixDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA.
Children's Hospital of Philadelphia · USUniversity of Pennsylvania · USVanderbilt University · US

Funding

Translational Research Support CoreP30ES013508 · NIEHS · UNIVERSITY OF PENNSYLVANIA · PI Rebecca A Simmons · 2006 to 2026
$35.3M
FUNCTION AND BIOLOGY OF EUKARYOTIC DNA TOPOISOMERASESR01GM033944 · NIGMS · VANDERBILT UNIVERSITY · PI OSHEROFF, NEIL · 1985 to 2015
$5.5M
MOLECULAR GENETIC CHANGES IN LEUKEMIA IN INFANTSR01CA080175 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI FELIX, CAROLYN A · 1999 to 2006
$2.2M
ANTINEOPLASTIC V LEUKEMOGENIC EPIPODOPHYLLOTOXIN EFFECTSR01CA077683 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI FELIX, CAROLYN A · 1999 to 2007
$1.9M
NCI NIH HHS R01 CA077683NCI NIH HHS R01 CA080175NIEHS NIH HHS P30 ES013508NIGMS NIH HHS R01 GM033944
6 · The paper itself

Abstract

Type II topoisomerases orchestrate proper DNA topology, and they are the targets of anti-cancer drugs that cause treatment-related leukemias with balanced translocations. Here, we develop a high-throughput sequencing technology to define TOP2 cleavage sites at single-base precision, and use the technology to characterize TOP2A cleavage genome-wide in the human K562 leukemia cell line. We find that TOP2A cleavage has functionally conserved local sequence preferences, occurs in cleavage cluster regions (CCRs), and is enriched in introns and lincRNA loci. TOP2A CCRs are biased toward the distal regions of gene bodies, and TOP2 poisons cause a proximal shift in their distribution. We find high TOP2A cleavage levels in genes involved in translocations in TOP2 poison-related leukemia. In addition, we find that a large proportion of genes involved in oncogenic translocations overall contain TOP2A CCRs. The TOP2A cleavage of coding and lincRNA genes is independently associated with both length and transcript abundance. Comparisons to ENCODE data reveal distinct TOP2A CCR clusters that overlap with marks of transcription, open chromatin, and enhancers. Our findings implicate TOP2A cleavage as a broad DNA damage mechanism in oncogenic translocations as well as a functional role of TOP2A cleavage in regulating transcription elongation and gene activation.

Indexed as

DNA DamageGenetic LociTranscription Elongation, GeneticDNA Topoisomerases, Type IIHumansK562 CellsLeukemiaNeoplasm ProteinsPoly-ADP-Ribose Binding ProteinsRNA, Long NoncodingDNA Topoisomerases, Type IINeoplasm ProteinsPoly-ADP-Ribose Binding ProteinsRNA, Long NoncodingTOP2A protein, human

Identifiers

PMID28385713
PMCPMC5495075
OpenAlexW2604275895

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.